View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
March 1, 2019updated 15 Mar 2019 6:41am

Medical devices industry deals for January 2019 total $3.61bn

Total medical devices industry deals in January 2019 worth $3.61bn were announced, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 188.8% over the previous month and a drop of 17.2% when compared with the last 12-month average of $4.36bn.

In terms of number of deals, the sector saw a rise of 11.43% over the last 12-month average with 117 deals against the average of 106 deals.

In value terms, North America led the activity with deals worth $3.11bn.

The top five medical devices deals accounted for 71.43% of the overall value in the sector globally during January 2019.

Medical devices industry deals in January 2019: Top deals

The combined value of the top five medical devices deals stood at $2.58bn, against the overall value of $3.61bn recorded for the month. The top announced medical devices deal tracked by GlobalData in January 2019 was PHC’s $1.14bn asset transaction with Thermo Fisher Scientific.

In second place was Silver Lake Partners’ private equity deal with Verily Life Sciences for $1bn and in third place was Qiagen’s $260m asset transaction with Formulatrix,.

CICC Capital Management, LB Investment, Meinian Onehealth Healthcare (Group), Ping An Insurance (Group) of China, Samsung Ventures Investment, Tasly Pharmaceutical Group’s $100m venture financing of Hangzhou KangSheng Health Management Consulting and Alychlo’s venture financing of Sophia Genetics for $77m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

Verdict’s parent company GlobalData plc provides business information to 4,000 of the world’s largest companies.

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU